What is VRCA's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.06B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VRCA?

P/E (TTM) is n/a and 52-week range is $3.25 to $9.82 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VRCA figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VRCA?

The company profile lists revenue (TTM) near $24M, net income (TTM) near -$2.51B, EPS (TTM) near -$1.67 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Verrica Pharmaceuticals Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in West Chester, Pennsylvania, US, 17.2M shares outstanding, ISIN US92511W2070 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Verrica Pharmaceuticals Inc

$VRCA

Health Care · Pharmaceuticals

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 76 full-time employees. The company went IPO on 2018-06-15. The firm's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. The company is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Employees

Website

verrica.com/

IPO

2018-06-15

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US92511W2070

Headquarters

West Chester, Pennsylvania, US

Shares outstanding

17.2M

NAICS sector

Manufacturing

Institutional ownership

27.05%

Browse other companiesFree AI scores and summaries for more stocks